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Blood stage malaria parasites causing a mild and self limited infection in mice have been obtained with
either radiation or chemical mutagenesis showing the possibility of developing an attenuated malaria
vaccine. Targeted disruption of plasmepsin-4 (pm4) or the merozoite surface protein-7 (msp7) genes also
induces a virulence-attenuated phenotype in terms of absence of experimental cerebral malaria (ECM),
delayed increase of parasitemia and reduced mortality rate. The decrease in virulence in parasites lacking
either pm4 or msp7 is however incomplete and dependent on the parasite and mouse strain combination.
The sequential disruption of both genes induced remarkable virulence-attenuated blood-stage parasites
characterized by a self-resolving infection with low levels of parasitemia and no ECM. Furthermore,
convalescent mice were protected against the challenge with P. berghei or P. yoelii parasites for several
months.Theseobservationsprovideaproof-of-conceptstepforthedevelopmentofhumanmalariavaccines
based on genetically attenuated blood-stage parasites.
P
lasmodium falciparum infection causes in non immune individuals a number of life threatening complica-
tionsincluding metabolic acidosis,respiratory distress,severe anemiaandneurological syndromeknown as
cerebral malaria that account for the death of about one million children every year in malaria endemic
regions. The key pathological features of severe malaria include the obstruction of microvascular districts by
parasitizederythrocytes,therapidexpansionoftheparasitemass,thedestructionofinfectederythrocytesandthe
activation of inflammatory processes
1–3. The sequestration of parasitized erythrocytes to different vascular dis-
tricts plays a major role in determining the organs and the tissues affected in some situations such as the brain in
cerebral malaria and the placenta in pregnant women
4–8. Members of the highly polymorphic P. falciparum
erythrocyte membrane protein1 family havebeen shown toplay acritical function inthis process
9–11.The role of
other factors such as the parasite mass and the growth rate in determining the pathology and the severity of the
infection is less clear. Althoughgene targeting technology has dramatically enhanced our molecular understand-
ingofP.falciparum
12–15bloodstagelifecycleintermsofitsmetabolism,growthrateanderythrocyteinvasion,the
roleofindividualgenesinshapingparasitevirulenceismuchlessclearbecauseofthelackofsuitableexperimental
models of human malaria
16–21. The infection caused by Plasmodium berghei in rodents partially mimics human
malaria and is regarded as a valuable in vivo model to study parasite induced pathology and the development of
protectiveimmunity.InP.berghei,similarlytowhathasbeenobservedforP.falciparum,disruptionofimportant
blood-stage transcribed genes is very difficult to accomplish
22–25. Only a small number of blood-stage genes,
including msp7 and pm4, have been disrupted in both P. berghei and P. falciparum allowing the analysis of how
impairment of in vitro growth translates into a virulence change of rodent malaria in vivo
23,26–28.
In P. falciparum the disruption of the msp7 gene, a member of a multigene family comprising msp7 and five
msp7-related protein (MSRP) genes
29, significantly impairs merozoites invasion of erythrocytes
27. In the rodent
malariaparasites P.berghei,thatcontains asinglemsp7gene andtwoMSRP genes
23,30,targetingofmsp7doesnot
induceadramaticinvivophenotype.Theseparasitesshowamorepronouncedreticulocyte-tropiccellpreference
but only a mild growth delay can be observed in infected mice
23.I nP. falciparum the disruption of pm4, the
aspartic protease that functions in the lysosomal compartment and contributes to hemoglobin digestion, causes
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26.
Similarly only a modest retardation in the asexual blood-stage
growth rate both in vitro and in vivo is observed in P. berghei para-
sites lacking pm4
28. Surprising this apparently insignificant growth
impairment translates into a dramatic decrease in in vivo virulence.
These parasites failed to induce experimental cerebral malaria
(ECM) in ECM-susceptible mice and ECM-resistant mice were able
to clear infection. Furthermore, after a single infection all conval-
escent mice were protected against subsequent challenge with lethal
parasites. To further investigate the relationship linking growth rate
and virulence we studied the phenotype of Dmsp7 parasites in terms
of ability to induce ECM and development of parasitemia in a num-
ber of mouse strains with different genetic backgrounds. We have
also generated parasites that lack both msp7 and pm4 to evaluate if
the combined gene disruption had an additive effect on the attenu-
ation of virulence.
Results
Development of MSP7 and PM4/MSP7 knockout P. berghei
parasites. A parasite strain lacking the msp7 gene has been already
developed few years ago, however because of the needof appropriate
controls we generated new parasites clones in which we have
disrupted the msp7 gene in both pbwt (Dmsp7 cl7 and Dmsp7 cl8)
and pbwt
1 genetic backgrounds
28,31 (Dmsp7
1) (Figure 1A). The
pbwt
1 parasites express a GFP-luciferase fusion protein under
the transcriptional control of the ama-1 promoter that allows the
monitoring of parasite load, distribution and patterns of schizont
sequestration in live mice by real time in vivo imaging. We
confirmed the disruption of the msp7 gene and the correct
integration of the replacement construct in all transgenic clones
by genomic diagnostic PCR (Figure 1B). Reverse transcription
(RT)-PCR (Figure 1C) and immunofluorescence analysis of mixed
blood-stage parasites (Figure 1D), from mice with high parasitemia,
confirmed the absence of msp7 transcript and protein in Dmsp7
clones. Double pm4 and msp7 knock-out parasite clones (Dpm4/
Dmsp7 cl4 and Dpm4/Dmsp7 cl12) were generated from two
independent transfection experiments, using a construct designed
to target the msp7 gene in the parasite line Dpm4 cl6 in which the
pm4 gene had been previously deleted
28 (Supplemental Figure 1A).
Correctdeletionofthemsp7geneandintegrationofthereplacement
construct in the double knock-out parasite was confirmed by
genomic diagnostic PCR (Supplemental Figure 1B). The lack of
both msp7 and pm4 transcripts was showed by RT-PCR analysis
from mixed blood-stage parasites (Supplemental Figure 1C).
Virulence phenotype of Dmsp7 and Dpm4/Dmsp7 parasites. We
have investigated in different mouse strains the virulence of Dmsp7
parasitesintermsofdevelopmentofpeakparasitemia,mortalityrate
andabilitytoinduceECM.Mousestrainsthatareknowntobeeither
resistant (BALB/c) or susceptible (C57BL/6 and CD1) to ECM were
infectedwithincreasingnumberofparasites.WeobservedinDmsp7
infected BALB/c mice only a mild delay in the parasite growth rate
during the initial phase of in vivo infection irrespectively of the
injection route (intravenous i.v. versus intraperitoneal i.p.)
(Figure 2A and 2B). The mice progressively developed a high
parasitemia and died during the third week post infection similarly
to pbwt-infected mice in agreement with previous reports
23. The
Dmsp7 parasites did not show in vivo anomalies in the process of
cell maturation and schizont development (not shown). We also
extended the characterization of the virulence phenotype of Dmsp7
parasites to ECM susceptible C57BL/6 mice. In this parasite-mouse
strain combination, Dmsp7 parasites showed a significant reduction
(p,0.001)onthegrowthrateuptoday12postinfectionandnotably
failed to induce signs and symptoms of ECM (Figure 3A, 3C and
Supplemental Figure 2A). These mice showed a prolonged course of
infection with increasing parasitemia and died during the fourth
week post infection with a peak parasitemia reaching 70%
(Figure 3A and 3B). On the contrary all pbwt-infected mice died at
around day 8 post-infection when the parasitemia was still low
(around 20%) developing a typical ECM pathology. Mice
inoculated with 10
5 or 10
6 Dmsp7 parasites consistently failed to
develop ECM suggesting that the absence of ECM in Dmsp7
infected mice did not depend on the level of parasitemia. The
virulence attenuated phenotype Dmsp7 parasites varied with the
mouse strain used. A substantial fraction of infected Dmsp7 CD1
mice (about 60%) died within 10 days post-infection with signs and
symptoms of ECM and with a parasitemia below 15% while the
others mice died later of severe anemia (Figure 3). The parasites in
which both pm4 and msp7 genes had been disrupted showed
irrespective of the mouse strain utilized a remarkable decrease in
the virulence that combined the individual phenotypes of the msp7
and pm4 knockout parasites. In BALB/c mice the growth rate of
Dpm4/Dmsp7 parasites was significantly delayed compared to
Dmsp7 parasites up to 12 days post-infection with a peak of
parasitemia at around day 21 that was rapidly cleared from the
blood resulting in undetectable parasitemia by microscopic
analysis by day 30 (Figure 2A and 2B). While C57BL/6 mice
infected with single Dpm4 and Dmsp7 parasites did not show any
signofECMbutdiedlaterofsevereanemia,mostofthemiceinfected
with Dpm4/Dmsp7 were able to control and completely clear the
parasites from the blood (Figure 3A). Notably Dpm4/Dmsp7
parasites induced in C57BL/6 mice a low peak parasitemia that
reached a maximum of 10% at day 12 post-infection and by day 25
the infection became undetectable by microscopic analysis
(Figure 3A). On the contrary single pm4 and msp7 knock out
parasites though failing to cause ECM in C57BL/6 mice
consistently induced high levels (up to 70%) of parasitemia. A
significant increased on the survival rate was observed in Dpm4/
Dmsp7 infected CD1 mice. The majority of the CD1 mice (about
60%) showed a decreased peak of parasitemia, survived the infection
and were able to clear the infected red blood cells (iRBCs) by day 30
post-injection (Figure 3). The remaining animals died after day 13
post-infection manly of severe anemia (Figure 3). All these results
indicated that virulence phenotype of Dpm4/Dmsp7 parasites was
dramatically reduced compared to wild type parasites and combines
traits of single pm4 or msp7 knock-out parasites.
To further investigate the virulence phenotype of Dpm4/Dmsp7
parasites we infected immunodeficient nude mice that are unable to
produce T-cells. Similarly to BALB/c mice all nude animals injected
with pbwt infected erythrocytes died within 20 days with high para-
sitemia (Figure 2C). On the contrary, the mice infected with Dpm4/
Dmsp7 survived for more than 50 days and showed low levels of
parasitemia in the first four weeks post infection (Figure 2C).
Comparable results were also obtained with NOD/SCID mice that
carried a combined B- and T-cell immunodeficiency infected with
Dpm4/Dmsp7 parasites (data not shown). These findings support
previous observation showing that T-cell deficient mice are unable
to resolve malaria infections
32. CD4
1 T cells play an important role
during the early stages of malarial infection, by amplifying the pha-
gocytic and cell-mediated anti-parasite responses; later in the infec-
tion, they help B cells to produce antibodies, and assist in regulating
the innate response
33–35.
Analysis of brain pathology in Dmsp7 and Dpm4/Dmsp7 infected
mousestrains.Thedevelopmentofcerebralpathologywasanalyzed
in ECM-susceptible C57BL/6 and CD1 mouse strains. In P. berghei
ECMis a wellcharacterized condition defined as the development of
cerebralcomplications(paralysis,deviationofthehead,convulsions,
coma) associated with a drop in body temperature to , 34uC, at day
6–10 after infection
2,36,37. In this study distinct groups of mice were
injected i.p. with 10
5–10
6 pbwt, Dmsp7 and Dpm4/Dmsp7 iRBC. In
C57BL/6 mice infected with pbwt we constantly observed clear
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 39 | DOI: 10.1038/srep00039 2Figure 1 | Targetedgenedisruptionofthemsp7locus. (a)SchematicrepresentationofthereplacementvectorpRSmsp7-tgdhfr/ts(i)andthemsp7locus
(ii). The wild-type msp7 locus is targeted with a linear fragment containing the 59 and 39 UTRs (striped bars) of the msp7 coding sequence (solid black
bars)andthe selectablemarkertgdhfr/ts(graybox).Theintegration ofthe construct bydoublecrossoverrecombination resultsinthereplacement ofthe
msp7genewiththetgdhfr/tsdrugselectablemarker(iii).ThepositionandorientationofprimersusedfordiagnosticPCRareindicatedwitharrowheads.
(b) Diagnostic PCR experiments to show the correct integration of the construct. The primer pairs 112 amplified a fragment of 1008 bp demonstrating
the presence of the intact msp7 locus in pbwt parasites, whereas no product was obtained with genomic DNA from Dmsp7 parasites clones. The primer
pairs 314 and 516 amplified a product of 558 bp and 452 bp respectively only in the genomic DNA from Dmsp7 parasites demonstrating the correct
integration of the construct. (c) In Dmsp7 parasites RT-PCR analysis failed to amplify the msp7 gene transcript from RNA of blood stage P. berghei
parasites.Asapositivecontrolspecificprimerswereusedtoamplifythetubtranscript.(d)Light-anddark-fieldimmunofluorescencemicrophotographs
of pbwt and Dmsp7 parasites analyzed by a polyclonal antibody directed against recombinant MSP7 protein. Bar indicates 50 mm.
www.nature.com/scientificreports
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ataxia, convulsions and coma) associated with a body temperature
dropbelow34uCsuggestingtheinsurgenceofECMbydaysevenpost
infectionwhereasthisoutcomewasneverobservedinC57BL/6mice
infected with Dmsp7 or Dpm4/Dmsp7 parasites (Figure 3C). We
investigated whether the failure of Dmsp7 parasites to cause ECM
was due to a modified sequestration pattern in vivo. We analyzed by
real time in vivo imaging the distribution of schizonts in tissues and
organsduringinfection
28,31,38.Synchronizedpbwt
1(controlline)and
Dmsp7
1 parasites expressing the luciferase gene under the
transcription control of the schizont-specific ama-1 promoter,
injected in CD1 mice showed similar levels of luminescence signal
inthelungs,theadiposetissueandthespleen,thusindicatingthatthe
disruption of msp7 did not affect the pattern of schizonts
sequestration in these organs and tissues (Supplemental Figure 3).
Furthermore pbwt
1 and Dmsp7
1 parasites showed a similar timing
ofpeakluciferaseactivitythusrulingoutthatthemutantparasiteline
had a marked impairment of the cell cycle development
(Supplemental Figure 3A). For the bioluminescence analysis we
infected groups of C57BL/6 mice with increasing numbers of
Dmsp7
1 parasites (ranging from 10
5–10
6) and as a control with 10
5
pbwt
1 parasites. At 7 days post infection we observed in the brains
isolated from pbwt
1infected C57BL/6 mice the presence of a strong
bioluminescence signal. In contrast, the brain of Dmsp7
1 infected
mice irrespectively of the infection dose and the level of parasitemia
showed only a low bioluminescent signal (Figure 4A). Quantitative
analysis demonstrated that the observed difference in
bioluminescence of pbwt
1 or Dmsp7
1 infected brains was
significant (Figure 4B). We also investigate the parasites burden
during the course of infection in others organs. The results
revealed that in CD1 mice pbwt
1 parasites are mostly confined in
thelungs(50–75%),intheadiposetissues(15–20%)andinthespleen
(7–15%) at day 5 post-infection without any relevant variation
during the remaining course of infection (Supplemental Figure 2B
and 2C). Mice infected with Dmsp7
1 parasites showed the same
organ distribution of the bioluminescent signal observed with
pbwt
1 parasites. An increase of signal in the adipose tissue and in
the spleen was observed from day 7 onwards post-infection. We
could not carry out a bioluminescence analysis of Dpm4/Dmsp7
parasites because the luciferase reporter is not present in the
parasite line. However, we previously reported a significant low
bioluminescent signal in the C57BL/6 mice infected with Dpm4
1
parasites compared to mice infected with pbwt
128.
To further investigate the development of ECM pathology we
examined the integrity of the blood-brain-barrier (BBB) in infected
mice using the Evans Blue dye extrusion analysis. Only brains from
Figure 2 | TimecourseofDmsp7andDpm4/Dmsp7infectionsinBALB/candnudemice. Thepercentageofsurvival(firstcolumn)andthetimecourse
of parasitemia (second column) are shown. BALB/c mice were inoculated either i.p. (a) (n510 per group) or i.v. (b) (n510 per group) with 10
7 and
50 infected erythrocytes respectively using Dmsp7, Dpm4/Dmsp7 and pbwt parasites. Parasitemia was daily evaluated by Giemsa stained thin blood
smears.MiceinfectedwithpbwtandDmsp7parasitessuccumbedinfectionwhileanimalsinfectedwithDpm4/Dmsp7survivedandclearedtheinfection.
(c) Nude mice (n510 per group) were injected i.p. with 10
7 pbwt or Dpm4/Dmsp7 parasites. In this parasite-mouse strain combination while most of
pbwt injected mice died of high parasitemia at around day 20, Dpm4/Dmsp7 injected mice showed very low levels of parasitemia in the first three weeks
post-infectionandsuccumbedtotheinfectiononlyaftertwomonthspost-injection.Thesedataarerepresentativeof2twoindependentexperiments.For
survival curve log rank test: *** p,0.001. For parasitemia Mann-Whitney test between transgenic and wild-type parasites: *** p,0.001.
www.nature.com/scientificreports
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1infectedanimalsshowedaclearbluecolorafterperfusionthat
was almost absent in the brains of mice infected with Dmsp7 and
Dpm4/Dmsp7 (Figure 4C). The quantification of Evans Blue in the
brains extract demonstrated that the infection with Dmsp7 and
Dpm4/Dmsp7 contrary to pbwt caused little damage to the BBB
(Figure 4D).
Dpm4/Dmsp7 infection induces a long lasting protective immu-
nityinconvalescentmice.BALB/c,C57BL/6andCD1micethathad
recovered from infection after a single injection of Dpm4/Dmsp7
parasites were challenged with pbwt iRBCs. All mice strains tested
wereprotectedagainstlethalparasitechallengegivenathighdosesof
10
7 (Table 1). Challenged mice showed a short-lasting and low level
parasitemia of ,0.01% that was usually cleared within 10 days. The
protection elicited by double knockout parasites was monitored for
up to six months after recovery from the initial infection. We also
performed sub-inoculation of blood from challenged animals into
naı ¨ve mice (n510) and none of them developed a detectable
parasitemia by microscopic analysis. Immunized mice were also
challenged with a different rodent malaria parasite species P. yoelii.
The immune response induced by Dpm4/Dmsp7 parasites protected
the mice also against the heterologous challenge with 10
4 P. yoelii
Figure 3 | TimecourseofDmsp7andDpm4/Dmsp7infectionsinC57BL/6andCD1mice. Thegraphsshowthe levelofparasitemia (a),the percentage
of survival (b) and the body temperature (c) in C57BL/6 mice (left panel) and CD1 mice (right panel) injected i.p. with 10
5 pbwt, Dmsp7 and
Dpm4/Dmsp7 parasites. C57BL/6 mice (n510 per group) infected with pbwt parasites died approximately 6–8 days post infection showing low level of
parasitemia (below 20%) and signs of ECM accompanied with hypothermia. On the contrary mice infected with Dmsp7 parasites did not show signs of
ECM,surviveduptotheforthweekpostinfectionanddiedshortlyafterwardswithveryhighparasitemia.MiceinfectedwithDpm4/Dmsp7didnotshow
signs of ECM, develop lower levels of parasitemia compared to pbwt and Dmsp7 parasites and cleared the infection by day 25. CD1 mice infected with
pbwt parasites died between day 8 to 12 post infection with a parasitemia of about 40% showing sign and symptoms of ECM. Some mice (around 40%)
infected with Dmsp7 parasites did not developed ECM and died within the third week post infection with high parasitemia. Most of the mice (60%)
infected with Dpm4/Dmsp7 parasites neither did developed neurological signs nor showed any drop in the body temperature. The animals that survived
infection showed lower levels of parasitemia compared to single Dmsp7 parasites and cleared the infection by day 30 post infection. The levels of
parasitemia of CD1mice infected with Dpm4/Dmsp7 represent the mean 6 SDfrom only the mice that survived infection. These data are representative
of2twoindependentexperiments.Forsurvival curve logranktest: *p,0.05, ***p,0.001.Forparasitemia Mann-Whitney testbetweentransgenic and
wild-type parasites: *** p,0.001.
www.nature.com/scientificreports
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infection by microscopic analysis.
Discussion
We show here that Dmsp7 parasites carrying a disrupted msp7 gene,
amutationpreviouslyreported tocauseamodestgrowthdelay, have
avirulenceattenuatedphenotype.WheninjectedtoECMsusceptible
C57BL/6 mice Dmsp7parasites didnot induce signs or symptoms of
cerebralmalaria.At7dayspost-infectionthebrainsofC57BL/6mice
infected with Dmsp7
1, a parasite line that carries a disrupted msp7
and expresses the luciferase gene under the transcription control of
the blood stage promoter ama-1, showed a much lower biolumin-
escent signal than the brains of pbwt
1 infected mice. Furthermore
unlikepbwt,theinfectioncausedbyDmsp7parasitesdidnotdamage
the blood brain barrier (BBB) as demonstrated by the distribution of
Evans Blue dye in isolated perfused brains. The ECM virulence
phenotype of Dmsp7 parasites is very similar to that observed in P.
berghei after disrupting the aspartic protease plasmepsin 4 gene
28
thought msp7 and pm4 are functionally unrelated. Parasites lacking
eitherpm4ormsp7haveincommonamildimpairmentoftheinvivo
growth.Possiblyareductionintheparasite growthrateandhence in
the parasite mass as well as in the products of parasite metabolism
may affect both the magnitude and the cytokine profile of the
immune response that in turn determine the occurrence of ECM
in susceptible animals. The recent observation that an imbalance
of the anti-inflammatory molecule heme oxygenase (HO)-1 and its
substrate heme (a product of hemoglobin degradation) has a role in
triggering ECM would support this notion
39. Indeed evidence origi-
natedfromotherrodentmalariaparasitessuggeststhatgrowthdelay
or drug mediated arrest in the erythrocytic cycle could translate into
asignificantreductionofvirulenceandintheinductionofprotective
immunity. As an example in P. yoelii the disruption of the gene
encoding the purine nucleoside phosphorylase (PNP) caused a sig-
nificantreductionofparasitegrowthandcausedaselflimitinginfec-
tion in vivo
40. Similarly, in this parasite species the disruption of the
nucleosidetransporter 1(NT1)generatedseverelyattenuated blood-
stage parasites that conferred complete sterile protection against
Figure 4 | Parasite distribution and blood vessel permeability in C57BL/6 infected mice. (a) Representative bioluminescent images of 7 days post
infectionbrainsisolatedfromC57BL/6miceinfectedwitheitherpbwt
1orDmsp7
1parasites.Thelevelofparasitemiaatthetimethebrainswerecollected
isshownaspercentageinthephotographpanels.(b)Quantitativeanalysisoftheluminescencesignalcollectedfromthebrainsofmiceinfectedwitheither
pbwt
1 or Dmsp7
1 parasites. Mann-Whitney test: * p,0.05. (c) Representative digital images of Evans Blue dye extrusion analysis of brains from pbwt,
Dmsp7 and Dmsp7/Dmsp7 infected C57BL/6 mice collected at day 7 post-infection. Only pbwt infected animals showed a blue staining post infusion
with Evans Blue dye that was nearly absent in the brains of Dmsp7 or Dmsp7/Dmsp7 infected mice. (d) Quantitative analysis of Evans Blue staining of
brains from infected mice (n56). Bars represent the mean 6 SD from 6 mice. Mann-Whitney test: * p,0.05, ** p,0.01.
Table 1 | Protection of Dpm4/Dmsp7 immunized mice against
challenged with P. berghei or P. yoelii.
Mouse
strain Challenge
Time of
challenge
(days)*
Challenge
dose (no. of
parasites)
{
No. protected/
challenged
BALB/c P. berghei (ANKA) 0 10
7 0/10
BALB/c ‘‘ 140 10
7 14/14
C57BL/6 ‘‘ 0 10
7 0/10
C57BL/6 ‘‘ 190 10
7 10/10
CD1 ‘‘ 0 10
7 0/10
CD1 ‘‘ 150 10
7 10/10
BALB/c P. yoelii (17X) 0 10
4 0/10
BALB/c ‘‘ 30 10
4 10/10
*Number of days after recovery from first infection with Dpm4/Dmsp7 parasites.
{Mice were challenged by i.v. injection of iRBCs
www.nature.com/scientificreports
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41. Furthermore, experi-
ments conducted on drug treated infected mice have shown that
timing and antigen dose play a critical role on the development of
an immune response
42–44. These studies have highlighted the poten-
tial importance of the early events in priming an immune response
and also the possible immunosuppressive effect of high levels of
parasitemia. Recent clinical studies indicate that a strong immune
protectiveresponsecouldbeelicitedbydrugcurelowdoseofbothP.
falciparum iRBCs or sporozoites
45,46. However a reduced parasite
growth rate is not invariably associated with an attenuated ECM
virulence phenotype. P. berghei parasites lacking the elongation fac-
tor1a(eef1a) have aslow growth rate due to aprolonged G1 phase
22,
butinduceECMinsusceptible mice.SimilarlycathepsinCknockout
parasites grow slower in vivo than the pbwt parental strain but are
able to induce ECM (unpublished observations RS).
With respect to the ability to reach sustained levels of parasitemia
Dmsp7 and Dpm4 parasites showed distinct phenotypes that varied
with the mouse strain utilized. In BALB/c mice, Dpm4 parasites
caused a self-resolving infection while in ECM susceptible C57BL/
6 and CD1 mice these parasites though failing to induce ECM pro-
gressively reached a high parasitemia and caused the death of the
animals
28.IrrespectivelyofthemousestrainutilizedDmsp7parasites
did not cause a self-resolving infection. The number of parasites in
the blood increased progressively until the death of the animals.
Notably the disruption of both pm4 and msp7 genes generated para-
sites that compared to the individual knockout strains showed a
more dramatic virulence attenuated phenotype that this time did
not vary with the genetic background of the mice. Irrespective of
the mouse strains utilized Dpm4/Dmsp7 parasites generally caused
a self-resolving infection that in a substantial fraction of the infected
micewasalsocharacterizedbyadrasticreductionoftheparasitemia.
Furthermore Dpm4/Dmsp7 parasites failed to induce ECM in sus-
ceptible mouse strains similar to what we observed in individual
knockout parasites. The self-resolving infection caused by double
knockout parasites was accompanied with a strong and long lasting
protective immune response against subsequent challenge with
homologous and heterologous parasites. Previous experiments con-
ducted with Dpm4 parasites have indicated that antibodies play a
crucial role in the protection elicited in these experimental models
28.
Inthispaper,weutilizedtheavailableknowledgeandpropertiesof
P. berghei iRBCs sequestration and used the recent advances in
in vivo imaging technologies to visualize parasite distribution and
loadindifferentorgansoflivemiceinfectedwithpbwt
1andDmsp7
1
parasitesthatexpress luciferase geneunderthecontrolofaschizont-
specific promoter (i.e., the ama-1). Imagings performed in experi-
mentallyinducedsynchronousinfectionsinmicewereestablishedby
injection of 0.5 to 1310
8 purified mature schizonts in four mice
31.
Collection of data at 21–23h after injection allowed the visualization
of sequesters parasites only in the lungs, adipose tissue and the
spleen
28,38. The luck of bioluminescence signal in the brain could
be due to several factors ranging from low level of parasites, below
the detection limit of the instruments, or to others factors such as
putative endothelial receptors expression, inflammatory markers
and adhesins that became up-regulated during infection. While
blood parasitemia has been routinely used to monitor disease pro-
gression, it is now recognized that measurements of total parasite
biomassinthewholebodyofferabettercorrelateofthediseasestatus
of malaria patients. Bioluminescence analysis of complete mice or
organs from different animals during ongoing infections can be
compared quantitatively and use to evaluate parasites burden.
Several recent studies have shown by in vivo imaging that the timing
of this iRBCs accumulation in the brain coincides with the develop-
mentofECMandmiceprotectedfromcerebralcomplicationsdonot
show a similar increase of iRBCs sequestration in the brain
28,38,47,48.
Anyway, bioluminescence alone could not be use to define precisely
the parasites burden in some organs (i.e., brain) and further analysis
are required. Parasites expressing different fluorescent reporter pro-
teins(e.g., GFPand mCherry) nowoffer the possibility toprovide an
insight into the amounts of parasites (i.e., load) that accumulate into
the organs to understand malaria pathology by, for example, using
multiphoton microscopy.
The enhanced virulence attenuation phenotype observed of
Dpm4/Dmsp7 parasites bears crucial implications for the develop-
ment of a malaria vaccine. The lack of significant progress with
subunitvaccinesthatcontainonly(partsof)singleproteins,together
with an enhanced understanding of the protective immunity to mal-
aria has generated new interest in vaccines based on whole blood
stageparasite
49.Sporozoitesthathavebeenattenuatedeitherbyradi-
ation or by genetic modification have shown promise as a whole
parasiteapproachtopre-erythrocyticvaccination
50–55.Recentstudies
have demonstrated that the disruption of individual genes was not
sufficient to completely attenuate parasite virulence. Infection with
p52-deficient sporozoites protected mice against subsequent infec-
tious sporozoite challenge, but the immunizations led to sporozoite
dose-dependent breakthrough infections
56,57. On the contrary spor-
ozoites lacking both p52 and p36 exhibited a complete growth arrest
in the liver in vitro
58. This study now demonstrates that sequential
disruption of specific blood-stage genes generates blood-stage para-
sites with a progressively virulence-attenuated phenotype that are
capable of inducing protective immunity in the P. berghei model of
malaria.Theseobservationsprovideacompellingcaseforgenerating
additional genetically attenuated blood stage (GABS) mutants for
assessing their potential usefulness in the development of GABS
based human malaria vaccines.
Methods
Mice and parasites. Six- to eight-week-old female C57BL/6 were purchased from
Charles River while CD1, BALB/c and nude mice were purchased from Harlan
Sprague. NOD/SCID (age 10–16 weeks) were kindly provided by Prof. Velardi and
Prof. Falini. All studies involving animals have been performed according to the D.L
27 January 1992, n. 116, Italian legislation. The parasite strain P. berghei ANKA was
used as a control for wild type parasite (pbwt) and for the generation of the mutant
lines Dmsp7 cl7 and Dmsp7 cl8. The msp7 gene (PBANKA_134910) has been
disrupted by introducing the construct pRSmsp7-tgdhfr/ts into the genome of
pbwt parasites by double cross-over recombination as described below. Clones
Dmsp7cl7andDmsp7cl8wereobtainedfromtwotransfectionexperiments.Dmsp7
1
is a mutant parasite line (Dmsp7 cl9) generated introducing construct pRSmsp7-
tgdhfr/ts into the genome of pbwt
1 parasites by double cross-over recombination.
The parasite strain pbwt
1 (1037cl1) is a reference transgenic parasite line that
expresses a fusion protein (GFP-Luc) encompassing the GFP (mutant3) and the
luciferase (LUC-IAV) coding sequence under the control of the schizont-specific
ama-1promoter
28.Dpm4/Dmsp7cl4andDpm4/Dmsp7cl12aretwomutantparasite
clones that are deficient in both pm4 and msp7 genes obtained by introducing
pRSmsp7-hdhfr construct into the genome of Dpm4 cl6 parasites line
28 by double
cross-over recombination.
Generation and analysis of Dmsp7 and Dpm4/Dmsp7 parasite lines. The DNA
plasmid pRSmsp7-tgdhfr/ts designed to target the msp7 locus of P. berghei ANKA
straincontainsthefollowingelements(Figure1A):i)a59UTR485bpPCRfragments
of the msp7 gene (sense: 59-CCGGGCCCGCGGGCTAGATTTAATCAGCAATTT-
GTC; ApaI site is underline and antisense: 59-CCATCGATTTTGTCTAAATATA-
TGTGTGTGTATG;ClaIsiteisunderline);ii)a39UTR375bpPCRfragments(sense:
59-GGAATTCATTATGTACACAGGAAATACATATAAAAC; EcoRI site is
underline and antisense: 59-CGGGATCCCAATGTTACCGAAGAAAAATA-
CAAAC; BamHI site is underline); iii) the Toxoplasma gondii dihydrofolate
reductase/thymidylate synthase (tgdhfr/ts) selectable marker cassette. The plasmid
was linearised with SacII and used for the generation of mutant lines Dmsp7 cl7,
Dmsp7 cl8 and Dmsp7
1 as described below
59. The structure of the msp7 locus in
transformed and wt parasites was analyzed in PCR experiments (Figure 1B) using
primer pair 112 (n.1: 59-ATGATGGCATATAAAAAGTTA TGTTTTTTA G; n.2:
59-TTATTTAAGATCAACTGTAGCTAAGG) under conditions where the msp7
sequence is readily amplified from pbwt (Figure 1B). The expected integration into
the msp7 locus was verified by successfully amplifying the predicted 59 and 39
boundarysequencesusingprimerpairs314(n.3:59-ACTGGAGCAACATGCGGAC;
n.4: 59- CAAACATACAAAAATAAACACC) and 516( n . 5 :5 9- TATATAATTTGT-
GAGGGATATG; n.6: 59-GTCGTATTCCCAATATTTACTAC) as shown in
Figure 1B. For RT-PCR total RNA from mixed blood-stage parasites was extracted
using TRIzol reagent (Invitrogen) and treated with TURBO DNase (Ambion).
cDNA synthesis was performed using the Super script III Platinum two-step
qRT-PCR kit (Invitrogen). The amplification of msp7 gene was performed with
primer pair 112 (see Figure 1A) and as a control the tubulin gene was amplified with
www.nature.com/scientificreports
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59-ACCTGACATAGCGGCTGAAA (Figure 1C and S1C). The lack of MSP7
expression was confirmed by immunofluorescence experiments using anti-PbMSP7
antibody raised in a mouse immunized with the recombinant protein. For protein
expression a region of the msp7 coding sequence was amplified with the following
primers: sense 59-CACCATGATGGCATATAAAAAGTTATGTTTTTTAG and
antisense 59-TTATTTAAGATCAACTGTAGCTAAGG and cloned into pEXP1-
DEST GatewayH Invitrogen vector. Cell lines BL21 StarH pLysS (Invitrogen) were
transformed and the recombinant protein purified by Ni-NTA Spin Kit (Qiagen) after
IPTG (1mM) induction. Female BALB/c mice were immunized four times with 50 mg
of purified protein. The sera from immunized mice was analyzed by immuno-
microarray technology (data not shown) and used in immunofluorescence assay at
15500 dilution. Antibody bound to the blood-stage parasites was visualized following
incubation with a secondary antibody goat anti-mouse (FITC conjugated)
(Figure 1D). VECTASHIELD Mounting Medium with DAPI (Vector) Labs) was used
to stain the nuclei of parasites. The images were captured by Nikon Eclipse TE2000-U
microscopy and analyzed with NIS-Elements imaging software. The DNA plasmid
pRSpm7-hdhfr (Figure S1A), designed to target the msp7 locus in the Dpm4 cl6
background parasites (that already contain the tgdhfr/ts selectable marker used for the
deletion of pm4 gene), was obtained from plasmid pRSpm7-tgdhfr/ts by the exchange
of tgdhfr/ts selectable marker cassette with the human dihydrofolate reductase (hdhfr)
selectable marker cassette. The hdhfr cassette was obtained from plasmid pL0008
(MR4) by PstIa n dEcoRI digestion and cloned into the plasmid pRSpm7-tgdhfr/ts.
The plasmid was linearized with SacII and used for the generation of mutant lines
Dpm4/Dmsp7 cl4 and Dpm4/Dmsp7 cl12. The disruption of the msp7 locus by
plasmid pRSpm7-hdhfr in these parasites line was analyzed by PCR reaction using
primer pair 112 as describe above (Figure 1SB). Integration specific PCR was
performed to confirm plasmid insertion in the msp7 locus using primers pair: 317
(n. 3 as above; n.7: 59-AGCACAATATCTAGGATACTAC) to analyze the 59UTR
integration site and primer pair 816( n .6a sa b o v e ;n .8 :5 9-ATGGTTGGTTCGCT-
AAACTGCATCG) to investigate the 39UTR integration site (Figure S1B). For the
generation of all mutant lines blood-stages parasites were transfected with 5–10 mgo f
gel-purified DNA linear fragments and mutant parasites were obtained by the
standard method of drug selection by pyrimethamine or WR92210 (kindly provided
by Jacobus Pharmaceutical Company) in mice
59. We enriched the recombinant
genotype in the parental transfected parasites population after at least four repeated
drugselectiontreatmentsuntilnowild-typegenotypewasdetectablebygenomicPCR.
Resistant parasites were subsequently cloned by limiting dilution as previously
described
59.
Monitoringofparasiteinfection.ThecourseofinfectioninBALB/cmice,whichare
not susceptible to ECM, was analyzed after either intraperitoneal (i.p) or
intravenously (i.v) inoculations of 10
7 or 50 infected red blood cells (iRBCs)
respectively. The parasitemia (5% of infected erythrocytes) was determined by
countingdailyGiemsastainedslidesoftailblood.Challengeexperimentswerecarried
out by i.v. injection of pbwt or P. yoelii 17X iRBCs.
Assessment of ECM. The development of cerebral complications was analyzed in
C57BL/6 and CD1 mice that are susceptible to ECM. This condition in P. berghei is
wellcharacterized anddefinedas thedevelopmentofcerebralcomplications (dropin
body temperature ,34uC, ataxia, paralysis, convulsions, coma) at day 6–9 after
infectionofmicewith10
4to10
6parasites
2,37.Inthisstudymicewereinjectedi.p.with
10
5 iRBCs (Dmsp7 and Dpm4/Dmsp7 infected mice were also infected with higher
dose (10
6 to 10
7) because of the low growth rate of parasites). The onset of cerebral
complications was determined by observing several clinical signs such as ruffled fur,
hunching, limb paralysis, coma and by measuring the drop in body temperature at
day 5–8 after infection. The body temperature was measured using a 2 Channel
Thermometer TK 98802 (2 Biological Instruments) with a rectal probe for mice. A
drop in temperature below 34uC is indicative of cerebral complications
36.
For the analysis of blood-brain-barrier (BBB) damage and vascular permeability
C57BL/6 mice 7 days post infection had been injected i.v. with 2% Evans Blue
60. Two
hours after dye injection the mice were perfused with heparinized PBS. The brain
weredissected, weighted, digitalimagecollected,frozeninLN2,andstoredat280uC.
Brain samples were homogenized in 1 mL of 50% trichloroacetic acid and stored
overnight at 4uC. The supernatant was obtained by centrifugation at 21.000 g for
30 minutes. The amount of Evans Blue dye was measured by a microplate reader
(excitation 600 nm, emission 650 nm) and quantified according to a standard curve.
Results are expressed as ng of Evans Blue per mg of brain tissue. Bioluminescence
analysis and signal quantification from brain of C57BL/6 mice with asynchronous
infection at day 7 post injection was performed after extensive intracardiac perfusion
of the animals with heparinized PBS by in vivo Imaging System (IVIS 200, Xenogen)
as described
28. Imaging data were analyzed using the programs LIVING IMAGE
(Xenogen) and IGOR PRO (WaveMetrics).
Analysisofparasitedistributioninliveanimalsandisolatedorgans.Sequestration
of schizonts in whole bodies of live CD1 mice and isolated organs was visualized
through imaging of luciferase-expressing, transgenic parasites with an intensified-
charge-coupleddevice(I-CCD)photoncountingvideocameraoftheinvivoImaging
System (IVIS200 Xenogen) as described
38,39. Sequestration patterns were monitored
in mice with synchronized infections of schizonts. Infections (1–3% parasitemia)
were established by injection of cultured, purified schizonts. Imaging was performed
between 17h and 23h after injection of schizonts. Imaging of individual organs,
obtained by dissection from animals at 21h, was done as described previously
38.
Imaging data were analyzed by using the programs LIVING IMAGE (Xenogen) and
IGOR PRO (WaveMetrics).
Statistical analyses. Differences in survival of different groups were analysed using
the Kaplan-Meier log-rank test. Differences in the parasitemia and bioluminescence
were performed using the Mann-Whitney nonparametric test. For all statistical test,
p,0.05wasconsidered significant.Inallfigures,*,**,***denotepvalueofp,0.05,
p,0.01 e p,0.001 respectively.
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